11月21日，海辰药业盘中下跌2.12%，截至09:35，报58.07元/股，成交5327.78万元，换手率1.11%，总 市值69.68亿元。 资金流向方面，主力资金净流出92.90万元，特大单买入139.00万元，占比2.61%，卖出0.00元，占比 0.00%；大单买入917.99万元，占比17.23%，卖出1149.89万元，占比21.58%。 海辰药业今年以来股价涨189.48%，近5个交易日跌19.24%，近20日涨9.13%，近60日涨9.73%。 海辰药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：电解液、原料药、锂电 池、固态电池、肝炎治疗等。 截至11月10日，海辰药业股东户数2.21万，较上期减少2.84%；人均流通股3709股，较上期增加2.93%。 2025年1月-9月，海辰药业实现营业收入4.72亿元，同比增长30.80%；归母净利润3267.85万元，同比增 长16.22%。 分红方面，海辰药业A股上市后累计派现1.61亿元。近三年，累计派现1800.00万元。 机构持仓方面，截止2025年9月30日，海辰药业十大流通股东中，中欧悦享生活混合A（010336） ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301507 | 民生健康 | 16.69 | -6.18% | 27.34万 | 4.63亿 | | 300452 | 山河药辅 | 14.40 | -4.45% | 27.33万 | 3.98亿 | | 002900 | 哈三联 | 13.74 | -4.12% | 12.95万 | 1.80亿 | | 300584 | 海辰药业 | 59.33 | -3.64% | 9.03万 | 5.51亿 | | 600513 | 联环药业 | 20.03 | -3.61% | 17.35万 | 3.51亿 | | 603367 | 辰欣药业 | 19.01 | -3.21% | 16.14万 | 3.11亿 | | 002693 | *ST双成 | 7.80 | -2.99% | 14.25万 | 1.12亿 | | 688356 | 键凯科技 | 82.86 | -2.93% | 8838.79 | 7365.18万 | | 300401 | 花园生 ...

11月18日，海辰药业跌5.19%，截至发稿，报65.55元/股，成交3.97亿元，换手率7.14%，总市值78.66亿 元。 资料显示，南京海辰药业股份有限公司位于江苏省南京经济技术开发区恒发路1号，成立日期2003年1月 15日，上市日期2017年1月12日，公司主营业务涉及化学制剂、原料药及中间体的研发、生产、销售。 主营业务收入构成为：心脑血管类87.12%，抗生素类5.69%，原料药及中间体1.68%，消化类1.50%，抗 病毒类1.47%，其他(补充)0.83%，免疫调节类0.80%，其他类0.57%，利尿类0.34%。 从海辰药业十大流通股东角度 中欧悦享生活混合A（010336）基金经理为钱亚风云。 截至发稿，钱亚风云累计任职时间10年118天，现任基金资产总规模24.96亿元，任职期间最佳基金回报 242.9%， 任职期间最差基金回报-24.02%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，中欧基金旗下1只基金位居海 ...

海辰药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：电解液、原料药、锂电 池、固态电池、熊去氧胆酸等。 截至11月10日，海辰药业股东户数2.21万，较上期减少2.84%；人均流通股3709股，较上期增加2.93%。 2025年1月-9月，海辰药业实现营业收入4.72亿元，同比增长30.80%；归母净利润3267.85万元，同比增 长16.22%。 分红方面，海辰药业A股上市后累计派现1.61亿元。近三年，累计派现1800.00万元。 机构持仓方面，截止2025年9月30日，海辰药业十大流通股东中，中欧悦享生活混合A（010336）位居 第四大流通股东，持股93.70万股，为新进股东。华安医药生物股票发起式A（022690）位居第五大流通 股东，持股89.03万股，为新进股东。富国稳健增长混合A（010624）位居第六大流通股东，持股70.00 万股，为新进股东。永赢新材料智选混合发起A（024737）位居第九大流通股东，持股48.24万股，为新 进股东。南方创新驱动混合A（009929）位居第十大流通股东，持股40.08万股，为新进股东。 责任编辑：小浪快报 11月18日，海辰药业盘中下 ...

证券日报网讯 海辰药业11月14日在互动平台回答投资者提问时表示，公司电解液添加剂详细产能可见 公司历年定期报告，目前主要给国内主要电解液厂供货。固态电池方面主要在硫化锂及粘结剂方面有所 布局，详细情况可参见公司定期报告。 （编辑 姚尧） ...

证券日报网讯海辰药业（300584）11月14日在互动平台回答投资者提问时表示，公司将视市场情况决定 投产计划。公司硫化锂已完成中试线建设，正在试生产；固态电池粘合剂正在小试工艺开发。 ...

Group 1: Company Announcements - 合富中国's stock price increased by 256.29% over 14 trading days, significantly outperforming the industry and Shanghai Composite Index, leading to a suspension for verification starting November 17 [1] - 工业富联's GB300 achieved mass production in Q3, with improved yield and testing efficiency, positively impacting Q4 gross margin [2] - 天孚通信's controlling shareholder plans to transfer 8.5 million shares, representing 1.09% of total equity, due to personal funding needs [4] - 璞泰来 plans to invest 7.6 billion yuan in a new integrated film coating project, aiming to meet growing demand in the battery and energy storage sectors [5] - 电投能源 intends to acquire 100% of Baiyin Hua Coal Power for 11.149 billion yuan, financing through share issuance and cash [6] - 中微公司 reported that a shareholder completed a reduction of 12.52 million shares, totaling 3.351 billion yuan [7] - 瑞德智能 plans to invest 10 million yuan in a leading company in the power plant robotics sector [8] - 盘古智能 aims to acquire control of a petrochemical company by purchasing 11.97% of its shares for 24.64 million yuan [9] - 泰达股份 signed a memorandum for a waste-to-energy project in Egypt [10] - 杭氧股份 is set to establish a venture capital fund focusing on low-temperature technology and nuclear fusion [11] Group 2: Financial Performance and Regulatory Approvals - 复星医药's subsidiary received FDA approval for a biosimilar drug, with applications pending in China and Europe [21] - 长春高新 received approval for a clinical trial of a new growth hormone drug, with no similar products currently available in China [20] - 海辰药业 obtained a drug registration certificate for a new injection product [22] - 上海机场 reported a 12.46% year-on-year increase in passenger throughput for October [23] Group 3: Shareholder Actions - 深桑达 A plans to publicly transfer 80% of a subsidiary's shares with a minimum price of 1.857 billion yuan [12] - 中电港's major shareholder reduced its stake by 1% between October 31 and November 13 [15] - 康龙化成's major shareholders plan to collectively reduce their holdings by up to 1.5% [16] - 科兴制药's controlling shareholder intends to transfer 5% of its shares [17]

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]

资金流向方面，高换手率个股中，有20股今日获主力资金净流入，净流入金额较多的有海辰药业、中富 通、康芝药业，净流入金额分别为2.99亿元、2.87亿元、2.58亿元，净流出金额较多的有富祥药业、上 能电气、值得买，净流出金额分别为5.32亿元、4.54亿元、2.35亿元。（数据宝） 11月14日创业板换手率居前个股 | 代码 | 简称 | 最新收盘价 | 日涨跌幅（%） | 日换手率（%） | 资金净流入（万元） | | --- | --- | --- | --- | --- | --- | | 300062 | 中能电气 | 11.61 | 6.32 | 51.59 | 2451.12 | | 301584 | 建发致新 | 36.00 | -3.33 | 46.67 | -4991.15 | | 301507 | 民生健康 | 17.79 | 7.62 | 43.62 | 4062.18 | | 300497 | 富祥药业 | 18.86 | 7.77 | 42.68 | -53238.14 | | 300785 | 值得买 | 38.80 | -4.06 | 36.99 | -23459.41 | | ...

医药生物行业今日上涨0.17%，全天主力资金净流入6.80亿元，该行业所属的个股共477只，今日上涨的 有283只，涨停的有15只；下跌的有183只。以资金流向数据进行统计，该行业资金净流入的个股有216 只，其中，净流入资金超亿元的有8只，净流入资金居首的是众生药业，今日净流入资金7.32亿元，紧 随其后的是海辰药业、特一药业，净流入资金分别为2.99亿元、2.99亿元。医药生物行业资金净流出个 股中，资金净流出超5000万元的有11只，净流出资金居前的有富祥药业、合富中国、人民同泰，净流出 资金分别为5.32亿元、3.38亿元、1.26亿元。（数据宝） 医药生物行业资金流入榜 沪指11月14日下跌0.97%，申万所属行业中，今日上涨的有4个，涨幅居前的行业为综合、房地产，涨 幅分别为1.58%、0.39%。医药生物行业今日上涨0.17%。跌幅居前的行业为电子、通信，跌幅分别为 3.09%、2.46%。 资金面上看，两市主力资金全天净流出813.21亿元，今日有5个行业主力资金净流入，医药生物行业主 力资金净流入规模居首，该行业今日上涨0.17%，全天净流入资金6.80亿元，其次是国防军工行业，日 跌幅为0 ...